Monalizumab

First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with mycosis fungoides that express KIR3DL2 New pre...

AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-breaking abstract on COAST Phase 2 trial Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the...

• Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphoma • Company’s...

Phase 2 expansion cohort data supports ongoing Phase 3 trial Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that it will...

Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy and...

Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Sézary syndrome and mycosis fungoides Monalizumab Phase 3 study expected to initiate in the second half of 2020...

Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rate Data confirm previous preliminary efficacy data seen in this subpopulation Innate Pharma SA (Euronext Paris...

Cash, cash equivalents and financial assets of the Company amounted to €215.2 million* $79.1 million (€71.4 million**) in gross proceeds from our IPO on the Nasdaq and Global Offering Monalizumab to...

IPH5401 dose-escalation study in advanced solid tumors, STELLAR-001, shows manageable safety profile Initiation of two expansion cohorts in non-small cell lung cancer (NSCLC) with secondary resistance...

Innate Pharma SA (the “Company” or “Innate” - Euronext Paris: FR0010331421 – IPH), today announced that AstraZeneca (LSE/STO/NYSE: AZN) will advance monalizumab into a Phase III randomized clinical...